Naisylate, 600 mg 20 pcs.

Pharmacodynamics

Amtolmethine guacil is a non-steroidal anti-inflammatory drug (NSAID), a non-selective cyclooxygenase inhibitor (COX). Amtolmethine guacil is a precursor of tolmethine. It has anti-inflammatory, analgesic, antipyretic, desensitizing effect, has gastroprotective effect. It suppresses pro-inflammatory factors, decreases platelet aggregation, inhibits COX-1 and COX-2, disrupts arachidonic acid metabolism, decreases prostaglandin formation (including in inflammation focus), suppresses exudative and proliferative phases of inflammation. It decreases capillary permeability, stabilizes lysosomal membranes, inhibits synthesis or inactivates inflammatory mediators (prostaglandins, histamine, bradykinins, cytokines, complement factors).

Indications

Active ingredient

How to take, the dosage

The recommended dose of amtolmethine guacil is 600 mg twice daily.

The maintenance dose can be reduced to 600 mg once daily depending on the degree of symptom control. The maximum daily dose is 1800 mg.

In order to maintain the gastroprotective effects of Naisylate®, it should be taken on an empty stomach.

Interaction

Inducers of microsomal oxidation in the liver (phenytoin, ethanol, barbiturates, rifampicin, phenylbutazone, tricyclic antidepressants) increase the production of hydroxylated active metabolites.

Decreases the effectiveness of uricosuric, hypotensive drugs and diuretics.

Accelerates the hypoglycemic effect of sulfonylurea derivatives, the effect of anticoagulants, antiaggregants, fibrinolytics, the side effects of estrogens, GCS and mineralocorticoids.

Antacids and colestiramine reduce absorption.

Increases blood concentrations of lithium drugs, methotrexate.

In some patients with impaired renal function, co-administration of NSAIDs and ACE inhibitors may lead to further impairment of renal function.

Myelotoxic drugs increase the manifestation of hematotoxicity of the drug.

Special Instructions

During treatment with Naisylate, monitoring of peripheral blood counts and functional status of the liver and kidneys is necessary.

The treatment should be stopped 48 hours before determination of 17-ketosteroids.

At the time of treatment, it is necessary to refrain from potentially hazardous activities requiring increased attention and rapid mental and motor reactions.

Contraindications

Side effects

Overdose

Symptoms:

Abdominal pain, nausea, vomiting, gastrointestinal tract erosive and ulcerative lesions, impaired renal function, metabolic acidosis.

Treatment:

Gastric lavage, administration of adsorbents (activated charcoal) and symptomatic therapy (maintenance of vital body functions). There is no specific antidote.

Pregnancy use